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Many women who inject drugs face discrimination on the basis of both drug use
and gender, increasing their vulnerability to HIV, violence, and other harms.
Punitive policies and practices from governments, health care systems, and law
enforcement, among others, drive women drug users away from life-saving care,
and have a particularly negative impact on pregnant and parenting drug users
and their children. When women drug users do reach services—whether at a site
offering needle exchange and other services to reduce the harms associated with
drug use, a drug treatment center, a women’s health clinic, or a women’s shelter—
they often find them unwelcoming and poorly suited to their needs. 
Women Drug Users and HIV 
Some researchers have found that for women who inject
drugs, sexual behavior is a greater predictor of HIV risk
than injecting practices such as sharing syringes.1
Women are more vulnerable to HIV during vaginal sex,
and women who inject drugs are more likely to experi-
ence HIV risk factors such as:
• having a sexual partner who injects drugs;2
• using drugs and sharing syringes with sexual
partners; 3
• experiencing sexual violence, including sexual
abuse from the police; 4,5
• exchanging sex for money, drugs, protection, food,
or shelter. 6
Despite the clear link between drug use and sexual risk
behaviors, few women’s health services worldwide
incorporate harm reduction, and women who inject
drugs are shut out of mainstream health and social
services that can directly or indirectly help them with the
challenges they face. 
Pregnancy, Motherhood, and Drug Use: 
A Need for Care, Not Prosecution
Pregnancy is a powerful motivator to reduce or cease
drug use and risky behaviors. Yet pregnant and parenting
drug users are often punished rather than given the
medical and social support they need. Punitive, stigmatiz-
ing policies and practices violate women drug users’
reproductive and human rights, drive women away from
life-saving services, and endanger the safety and survival
of their children. 
• In some countries, including parts of Eastern
Europe, pregnant drug users are rejected by
obstetricians, denied accurate information about
prevention of mother-to-child transmission of HIV
(PMTCT) and the effects of drug use during
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pregnancy, and pressured or coerced to have
abortions or give their children up for adoption.7
• Throughout the world, few drug treatment
programs provide child care or other accommoda-
tion for women with children. Many women
cannot leave their children and families to enter
inpatient drug treatment, and domestic responsi-
bilities can make it difficult for women to adhere
to the rigid schedules and requirements of
treatment programs. 8
• In Russia, treatment with methadone or
buprenorphine is unavailable, and in Eastern
Europe and Asia it is available to only a tiny
fraction of those who need it. 9 Opiate-dependent
women in these countries are denied a highly
effective outpatient treatment that helps prevent
drug-related harm to themselves and, if they are
pregnant, to their fetuses. 
• In the United States, pregnant drug users have
been criminally prosecuted for drug use during
pregnancy. 10,11 Drug charges often result in loss of
parental rights, though many women do not have
access to affordable treatment on demand. 12
• Confidentiality is of particular concern to women
drug users, who risk losing custody of their
children if their drug use is disclosed. In some
countries of Eastern Europe and Central Asia,
entry into drug treatment can be accompanied by
government registration as a drug user, and
patient lists are sometimes shared with the 
police. 13 In Russia, a diagnosis of drug addiction
can be legal grounds for loss of custody. 14
Protecting the Health and Rights 
of Women Who Use Drugs
Advocates for harm reduction and women’s health can
help women who inject drugs receive the care they need
by acting upon the following recommendations: 
1. Build alliances between the women’s health
community and the harm reduction community
to ensure that women drug users have easy access
to the services they need, including PMTCT,
informed reproductive choice, and methadone or
buprenorphine treatment and other forms of
effective drug treatment that accommodate
mothers
2. Train and support harm reduction programs to
incorporate sexual and reproductive health
services into their programs, including 
• counseling on PMTCT and harm 
reduction during pregnancy
• domestic violence and rape prevention
• social support to help women fulfill basic 
needs and avoid survival sex
• couples counseling to help women 
negotiate safer sex and drug use practices
3. Work with policymakers and service providers 
to ensure the confidentiality of women drug 
users who seek care
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Women and Harm Reduction at IHRD
With the support of the Canadian International Development Agency, the Open Society Institute’s International
Harm Reduction Development Program (IHRD) launched a new project in 2007 on women and harm reduction
in Georgia, Russia, and Ukraine. The project’s primary goals are to increase understanding of the gender
dynamics of drug use and access to appropriate services in the three countries; to identify the particular 
challenges faced by women in seeking harm reduction and reproductive health services, and health care in
general; and to engage in regulatory reform and professional education to remove these obstacles. 
For an in-depth discussion of these topics, please read IHRD’s publication Women, Harm Reduction, and HIV,
which is available with a footnoted version of this fact sheet at www.soros.org/harm-reduction
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